Literature DB >> 22106171

Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals.

Chi-Chi Peng1, Wei Shi, Justin D Lutz, Kent L Kunze, Jun O Liu, Wendel L Nelson, Nina Isoherranen.   

Abstract

Itraconazole (ITZ) is a mixture of four cis-stereoisomers that inhibit CYP3A4 potently and coordinate CYP3A4 heme via the triazole nitrogen. However, (2R,4S,2'R)-ITZ and (2R,4S,2'S)-ITZ also undergo stereoselective sequential metabolism by CYP3A4 at a site distant from the triazole ring to 3'-OH-ITZ, keto-ITZ, and N-desalkyl-ITZ. This stereoselective metabolism demonstrates specific interactions of ITZ within the CYP3A4 active site. To further investigate this process, the binding and metabolism of the four trans-ITZ stereoisomers by CYP3A4 were characterized. All four trans-ITZ stereoisomers were tight binding inhibitors of CYP3A4-mediated midazolam hydroxylation (IC(50) 16-26 nM), and each gave a type II spectrum upon binding to CYP3A4. However, instead of formation of 3'-OH-ITZ, they were oxidized at the dioxolane ring, leading to ring scission and formation of two new metabolites of ITZ. These two metabolites were also formed from the four cis-ITZ stereoisomers, although not as efficiently. The catalytic rates of dioxolane ring scission were similar to the dissociation rates of ITZ stereoisomers from CYP3A4, suggesting that the heme iron is reduced while the triazole moiety coordinates to it and no dissociation of ITZ is necessary before catalysis. The triazole containing metabolite [1-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-yl)ethanone] also inhibited CYP3A4 (IC(50) >15 μM) and showed type II binding with CYP3A4. The dioxolane ring scission appears to be clinically relevant because this metabolite was detected in urine samples from subjects that had been administered the mixture of cis-ITZ isomers. These data suggest that the dioxolane ring scission is a metabolic pathway for drugs that contain this moiety.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22106171      PMCID: PMC3286268          DOI: 10.1124/dmd.111.042739

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  17 in total

1.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. II. SOLUBILIZATION, PURIFICATION, AND PROPERTIES.

Authors:  T OMURA; R SATO
Journal:  J Biol Chem       Date:  1964-07       Impact factor: 5.157

2.  Stereochemical aspects of itraconazole metabolism in vitro and in vivo.

Authors:  Kent L Kunze; Wendel L Nelson; Evan D Kharasch; Kenneth E Thummel; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2006-01-13       Impact factor: 3.922

3.  The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam.

Authors:  K T Olkkola; J Ahonen; P J Neuvonen
Journal:  Anesth Analg       Date:  1996-03       Impact factor: 5.108

4.  Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data.

Authors:  I Templeton; C-C Peng; K E Thummel; C Davis; K L Kunze; N Isoherranen
Journal:  Clin Pharmacol Ther       Date:  2010-08-25       Impact factor: 6.875

5.  Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.

Authors:  P J Neuvonen; T Kantola; K T Kivistö
Journal:  Clin Pharmacol Ther       Date:  1998-03       Impact factor: 6.875

6.  Reconstitution premixes for assays using purified recombinant human cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b5.

Authors:  P M Shaw; N A Hosea; D V Thompson; J M Lenius; F P Guengerich
Journal:  Arch Biochem Biophys       Date:  1997-12-01       Impact factor: 4.013

Review 7.  Biochemical approaches to selective antifungal activity. Focus on azole antifungals.

Authors:  H Vanden Bossche; P Marichal; J Gorrens; M C Coene; G Willemsens; D Bellens; I Roels; H Moereels; P A Janssen
Journal:  Mycoses       Date:  1989       Impact factor: 4.377

8.  Impact of Absolute Stereochemistry on the Antiangiogenic and Antifungal Activities of Itraconazole.

Authors:  Wei Shi; Benjamin A Nacev; Shridhar Bhat; Jun O Liu
Journal:  ACS Med Chem Lett       Date:  2010       Impact factor: 4.345

9.  Role of itraconazole metabolites in CYP3A4 inhibition.

Authors:  Nina Isoherranen; Kent L Kunze; Kyle E Allen; Wendel L Nelson; Kenneth E Thummel
Journal:  Drug Metab Dispos       Date:  2004-07-08       Impact factor: 3.922

10.  Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo.

Authors:  I E Templeton; K E Thummel; E D Kharasch; K L Kunze; C Hoffer; W L Nelson; N Isoherranen
Journal:  Clin Pharmacol Ther       Date:  2007-05-09       Impact factor: 6.875

View more
  4 in total

1.  Effect of CYP3A5 and ABCB1 polymorphisms on the interaction between tacrolimus and itraconazole in patients with connective tissue disease.

Authors:  Masaru Togashi; Takenori Niioka; Atsushi Komatsuda; Mizuho Nara; Shin Okuyama; Ayumi Omokawa; Maiko Abumiya; Hideki Wakui; Naoto Takahashi; Masatomo Miura
Journal:  Eur J Clin Pharmacol       Date:  2015-07-17       Impact factor: 2.953

2.  1,2,3-Triazole-heme interactions in cytochrome P450: functionally competent triazole-water-heme complexes.

Authors:  Kip P Conner; Preethi Vennam; Caleb M Woods; Matthew D Krzyaniak; Michael K Bowman; William M Atkins
Journal:  Biochemistry       Date:  2012-07-31       Impact factor: 3.162

3.  Modified release itraconazole amorphous solid dispersion to treat Aspergillus fumigatus: importance of the animal model selection.

Authors:  Julien P Maincent; Laura K Najvar; William R Kirkpatrick; Siyuan Huang; Thomas F Patterson; Nathan P Wiederhold; Jay I Peters; Robert O Williams
Journal:  Drug Dev Ind Pharm       Date:  2016-10-05       Impact factor: 3.225

4.  Kinetics of cytochrome P450 3A4 inhibition by heterocyclic drugs defines a general sequential multi-step binding process.

Authors:  F Peter Guengerich; Kevin D McCarty; Jesse G Chapman
Journal:  J Biol Chem       Date:  2020-12-24       Impact factor: 5.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.